SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.
Identifieur interne : 000168 ( Main/Exploration ); précédent : 000167; suivant : 000169SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.
Auteurs : Peyman Kheirandish Zarandi [Iran] ; Mohammad Reza Zinatizadeh [Iran] ; Maryam Zinatizadeh [Iran] ; Mohammad Hadi Yousefi [Iran] ; Nima Rezaei [Iran]Source :
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [ 1950-6007 ] ; 2021.
Descripteurs français
- KwdFr :
- MESH :
- classification : Antiviraux.
- pharmacologie : Antiviraux.
- Essais cliniques comme sujet, Humains, Résultat thérapeutique.
English descriptors
- KwdEn :
- MESH :
- chemical , classification : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- drug effects : SARS-CoV-2.
- drug therapy : COVID-19.
- immunology : COVID-19.
- pathogenicity : SARS-CoV-2.
- physiology : SARS-CoV-2.
- physiopathology : COVID-19.
- Clinical Trials as Topic, Humans, Treatment Outcome.
Abstract
INTRODUCTION
The world is witnessing the spread of one of the members of Coronaviruses (CoVs) family, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the 21st century. Considering the short time spent after its prevalence, limited information is known about the effect of the virus mechanism on different organs of the body; meanwhile the lack of specific treatment and vaccine for this virus has exposed millions of people to a big challenge.
AREAS COVERED
The review article aims to describe the general and particular characteristics of CoVs, their classification, genome structure, host cell infection, cytokine storm, anti-viral treatments, and inhibition of COVID-19-related ER-mitochondrial stress. In addition, it refers to drugs such as Chloroquine/Hydroxychloroquine, Lopinavir/Ritonavir, darunavir, ribavirin, remdesivir, and favipiravir, which have undergone clinical trials for coronavirus disease 2019 (COVID-19) treatment. This analysis was derived from an extensive scientific literature search including Pubmed, ScienceDirect, and Google Scholar performed.
EXPERT OPINION
The effectiveness rate and complications of these drugs can reveal new insights into the potential therapeutic goals for the disease. Moreover, lifestyle change can effectively prevent SARS-CoV-2 infection.
DOI: 10.1016/j.biopha.2021.111352
PubMed: 33550050
PubMed Central: PMC7969672
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.</title><author><name sortKey="Zarandi, Peyman Kheirandish" sort="Zarandi, Peyman Kheirandish" uniqKey="Zarandi P" first="Peyman Kheirandish" last="Zarandi">Peyman Kheirandish Zarandi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Zinatizadeh, Mohammad Reza" sort="Zinatizadeh, Mohammad Reza" uniqKey="Zinatizadeh M" first="Mohammad Reza" last="Zinatizadeh">Mohammad Reza Zinatizadeh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: mr.zinatizadeh@srbiau.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Zinatizadeh, Maryam" sort="Zinatizadeh, Maryam" uniqKey="Zinatizadeh M" first="Maryam" last="Zinatizadeh">Maryam Zinatizadeh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesiology, Semnan Branch, Islamic Azad University, Shahrood, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Anesthesiology, Semnan Branch, Islamic Azad University, Shahrood</wicri:regionArea><wicri:noRegion>Shahrood</wicri:noRegion></affiliation></author><author><name sortKey="Yousefi, Mohammad Hadi" sort="Yousefi, Mohammad Hadi" uniqKey="Yousefi M" first="Mohammad Hadi" last="Yousefi">Mohammad Hadi Yousefi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Rezaei, Nima" sort="Rezaei, Nima" uniqKey="Rezaei N" first="Nima" last="Rezaei">Nima Rezaei</name><affiliation wicri:level="1"><nlm:affiliation>Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: rezaei_nima@tums.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33550050</idno><idno type="pmid">33550050</idno><idno type="doi">10.1016/j.biopha.2021.111352</idno><idno type="pmc">PMC7969672</idno><idno type="wicri:Area/Main/Corpus">000378</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000378</idno><idno type="wicri:Area/Main/Curation">000378</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000378</idno><idno type="wicri:Area/Main/Exploration">000378</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.</title><author><name sortKey="Zarandi, Peyman Kheirandish" sort="Zarandi, Peyman Kheirandish" uniqKey="Zarandi P" first="Peyman Kheirandish" last="Zarandi">Peyman Kheirandish Zarandi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Zinatizadeh, Mohammad Reza" sort="Zinatizadeh, Mohammad Reza" uniqKey="Zinatizadeh M" first="Mohammad Reza" last="Zinatizadeh">Mohammad Reza Zinatizadeh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: mr.zinatizadeh@srbiau.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Zinatizadeh, Maryam" sort="Zinatizadeh, Maryam" uniqKey="Zinatizadeh M" first="Maryam" last="Zinatizadeh">Maryam Zinatizadeh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Anesthesiology, Semnan Branch, Islamic Azad University, Shahrood, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Anesthesiology, Semnan Branch, Islamic Azad University, Shahrood</wicri:regionArea><wicri:noRegion>Shahrood</wicri:noRegion></affiliation></author><author><name sortKey="Yousefi, Mohammad Hadi" sort="Yousefi, Mohammad Hadi" uniqKey="Yousefi M" first="Mohammad Hadi" last="Yousefi">Mohammad Hadi Yousefi</name><affiliation wicri:level="1"><nlm:affiliation>Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author><author><name sortKey="Rezaei, Nima" sort="Rezaei, Nima" uniqKey="Rezaei N" first="Nima" last="Rezaei">Nima Rezaei</name><affiliation wicri:level="1"><nlm:affiliation>Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: rezaei_nima@tums.ac.ir.</nlm:affiliation><country xml:lang="fr">Iran</country><wicri:regionArea>Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran</wicri:regionArea><wicri:noRegion>Tehran</wicri:noRegion></affiliation></author></analytic><series><title level="j">Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</title><idno type="eISSN">1950-6007</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (classification)</term><term>Antiviral Agents (pharmacology)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (immunology)</term><term>COVID-19 (physiopathology)</term><term>Clinical Trials as Topic (MeSH)</term><term>Humans (MeSH)</term><term>SARS-CoV-2 (drug effects)</term><term>SARS-CoV-2 (pathogenicity)</term><term>SARS-CoV-2 (physiology)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (classification)</term><term>Antiviraux (pharmacologie)</term><term>Essais cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Résultat thérapeutique (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="classification" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Essais cliniques comme sujet</term><term>Humains</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>INTRODUCTION</b></p><p>The world is witnessing the spread of one of the members of Coronaviruses (CoVs) family, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the 21st century. Considering the short time spent after its prevalence, limited information is known about the effect of the virus mechanism on different organs of the body; meanwhile the lack of specific treatment and vaccine for this virus has exposed millions of people to a big challenge.</p></div><div type="abstract" xml:lang="en"><p><b>AREAS COVERED</b></p><p>The review article aims to describe the general and particular characteristics of CoVs, their classification, genome structure, host cell infection, cytokine storm, anti-viral treatments, and inhibition of COVID-19-related ER-mitochondrial stress. In addition, it refers to drugs such as Chloroquine/Hydroxychloroquine, Lopinavir/Ritonavir, darunavir, ribavirin, remdesivir, and favipiravir, which have undergone clinical trials for coronavirus disease 2019 (COVID-19) treatment. This analysis was derived from an extensive scientific literature search including Pubmed, ScienceDirect, and Google Scholar performed.</p></div><div type="abstract" xml:lang="en"><p><b>EXPERT OPINION</b></p><p>The effectiveness rate and complications of these drugs can reveal new insights into the potential therapeutic goals for the disease. Moreover, lifestyle change can effectively prevent SARS-CoV-2 infection.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33550050</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1950-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><PubDate><Year>2021</Year><Month>May</Month></PubDate></JournalIssue><Title>Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie</Title><ISOAbbreviation>Biomed Pharmacother</ISOAbbreviation></Journal><ArticleTitle>SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.</ArticleTitle><Pagination><MedlinePgn>111352</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0753-3322(21)00137-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.biopha.2021.111352</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The world is witnessing the spread of one of the members of Coronaviruses (CoVs) family, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the 21st century. Considering the short time spent after its prevalence, limited information is known about the effect of the virus mechanism on different organs of the body; meanwhile the lack of specific treatment and vaccine for this virus has exposed millions of people to a big challenge.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="UNASSIGNED">The review article aims to describe the general and particular characteristics of CoVs, their classification, genome structure, host cell infection, cytokine storm, anti-viral treatments, and inhibition of COVID-19-related ER-mitochondrial stress. In addition, it refers to drugs such as Chloroquine/Hydroxychloroquine, Lopinavir/Ritonavir, darunavir, ribavirin, remdesivir, and favipiravir, which have undergone clinical trials for coronavirus disease 2019 (COVID-19) treatment. This analysis was derived from an extensive scientific literature search including Pubmed, ScienceDirect, and Google Scholar performed.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="UNASSIGNED">The effectiveness rate and complications of these drugs can reveal new insights into the potential therapeutic goals for the disease. Moreover, lifestyle change can effectively prevent SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Copyright © 2021. Published by Elsevier Masson SAS.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zarandi</LastName><ForeName>Peyman Kheirandish</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinatizadeh</LastName><ForeName>Mohammad Reza</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran; Cancer Biology Signaling Pathway Interest Group (CBSPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: mr.zinatizadeh@srbiau.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinatizadeh</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Semnan Branch, Islamic Azad University, Shahrood, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yousefi</LastName><ForeName>Mohammad Hadi</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; Department of Mycobacteriology and Pulmonary Research, Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezaei</LastName><ForeName>Nima</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: rezaei_nima@tums.ac.ir.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Biomed Pharmacother</MedlineTA><NlmUniqueID>8213295</NlmUniqueID><ISSNLinking>0753-3322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anti-viral treatments</Keyword><Keyword MajorTopicYN="N">Cytokine storm</Keyword><Keyword MajorTopicYN="N">MERS</Keyword><Keyword MajorTopicYN="N">Pathogenesis</Keyword><Keyword MajorTopicYN="N">SARS</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>20</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33550050</ArticleId><ArticleId IdType="pii">S0753-3322(21)00137-2</ArticleId><ArticleId IdType="doi">10.1016/j.biopha.2021.111352</ArticleId><ArticleId IdType="pmc">PMC7969672</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Iran</li></country></list><tree><country name="Iran"><noRegion><name sortKey="Zarandi, Peyman Kheirandish" sort="Zarandi, Peyman Kheirandish" uniqKey="Zarandi P" first="Peyman Kheirandish" last="Zarandi">Peyman Kheirandish Zarandi</name></noRegion><name sortKey="Rezaei, Nima" sort="Rezaei, Nima" uniqKey="Rezaei N" first="Nima" last="Rezaei">Nima Rezaei</name><name sortKey="Yousefi, Mohammad Hadi" sort="Yousefi, Mohammad Hadi" uniqKey="Yousefi M" first="Mohammad Hadi" last="Yousefi">Mohammad Hadi Yousefi</name><name sortKey="Zinatizadeh, Maryam" sort="Zinatizadeh, Maryam" uniqKey="Zinatizadeh M" first="Maryam" last="Zinatizadeh">Maryam Zinatizadeh</name><name sortKey="Zinatizadeh, Mohammad Reza" sort="Zinatizadeh, Mohammad Reza" uniqKey="Zinatizadeh M" first="Mohammad Reza" last="Zinatizadeh">Mohammad Reza Zinatizadeh</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000168 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000168 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33550050
|texte= SARS-CoV-2: From the pathogenesis to potential anti-viral treatments.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33550050" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |